ArticleJournal of molecular neuroscience : MN2003
Calpain inhibitors, a treatment for Alzheimer's disease: position paper.
Article in Journal of molecular neuroscience : MN, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 65 citations in OpenAlex.
- BDA-410 inhibits SARS-CoV-2 main protease activity and viral replication in mammalian cells.Journal of cellular and molecular medicine · 2022Article
- Memory and Learning Deficits Are Associated With CaFrontiers in aging neuroscience · 2020Article
- Article
- Involvement of calpain in the neuropathogenesis of Alzheimer's disease.Medicinal research reviews · 2019Review
- Calpain-1 regulates platelet function in a humanized mouse model of sickle cell disease.Thrombosis research · 2017Article
- Why calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis?Parasitology · 2017Review
- Administration of low dose estrogen attenuates gliosis and protects neurons in acute spinal cord injury in rats.Journal of neurochemistry · 2016Article
- Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors.Acta pharmaceutica Sinica. B · 2015Review
- Synaptic therapy in Alzheimer's disease: a CREB-centric approach.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015Review
- Neuroprotective strategies against calpain-mediated neurodegeneration.Neuropsychiatric disease and treatment · 2015Review
- Pharmacological inhibition of calpain-1 prevents red cell dehydration and reduces Gardos channel activity in a mouse model of sickle cell disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2013Article
- Calpains: potential targets for alternative chemotherapeutic intervention against human pathogenic trypanosomatids.Current medicinal chemistry · 2013Review
- Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?The Biochemical journal · 2012Review
- Calpain-mediated degradation of myocyte enhancer factor 2D contributes to excitotoxicity by activation of extrasynaptic N-methyl-D-aspartate receptors.The Journal of biological chemistry · 2012Article
- Calpain dysregulation in Alzheimer's disease.ISRN biochemistry · 2012Review
- Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice.Journal of cardiovascular pharmacology · 2012Article
- The ankyrin repeat-rich membrane spanning (ARMS)/Kidins220 scaffold protein is regulated by activity-dependent calpain proteolysis and modulates synaptic plasticity.The Journal of biological chemistry · 2010Article
- Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of central nervous system diseases.Neurobiology of disease · 2010Review
- Marked calpastatin (CAST) depletion in Alzheimer's disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2008Article
- The novel calpain inhibitor A-705253 potently inhibits oligomeric beta-amyloid-induced dynamin 1 and tau cleavage in hippocampal neurons.Neurochemistry international · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calpains modulate processes that govern the function and metabolism of proteins key to the pathogenesis of Alzheimer's disease, including tau and amyloid precursor protein. Because activation of the calpain system might contribute to the impairment of synaptic transmission in Alzheimer's disease, we are currently testing the hypotheses that a treatment with calpain inhibitors might restore normal cognition and synaptic transmission in a transgenic model of Alzheimer's disease, the APP (K670N:M671L)/PS1(M146L) mouse. Findings derived from these studies will provide a novel approach to cognitive enhancement in Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.